Announced Fri, 15 May · 19:22 IST

Outcome of Board Meeting

Revenue Growth 20pctPat Growth 25pctRelated Party TransactionsResults View source PDF

KIMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.4%1-day move
₹766.00
prior close
₹748.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+0.2+0.3+0.2-3.4-2.3+0.5-1.0-1.6+2.4+2.0+3.1+3.3
Up moveDown movePending
AI summary

Krishna Institute of Medical Sciences (KIMS) board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026. Consolidated revenue grew 23.4% to Rs 16,120 million from Rs 13,065 million. Profit after tax increased 38.3% to Rs 2,395 million from Rs 1,732 million. The auditors S.R. Batliboi & Associates LLP issued an unmodified (clean) opinion. The board appointed M/s. Sagar & Associates as Cost Auditors for FY 2026-27 and made senior management changes including a new CFO and Company Secretary re-designation. Mr. Adwik Bollineni was re-designated from Non-Executive to Executive Director. The 24th AGM is scheduled for August 27, 2026.

Likely market impact

Strong financial performance with over 20% revenue growth and PAT growth exceeding 25% will be viewed positively by shareholders. Clean audit opinion and management changes provide stability. The company continues expanding with significant capital investments reflected in growing asset base.